Searchable abstracts of presentations at key conferences in endocrinology

ea0031oc5.4 | Pituitary and neoplasia | SFEBES2013

Clinical, metabolic, biochemical and radiological characterisation of patients with thyrotropinomas reveals a highly variable phenotype

Koulouri Olympia , Moran Carla , Kandasamy Narayanan , Halsall David , Chatterjee Krish , Gurnell Mark

Background: Thyrotropinomas (TSHomas) are traditionally considered a rare albeit important cause of thyrotoxicosis, accounting for ∼1% of all pituitary adenomas. Although early case series reported a preponderance of macroadenomas, emerging evidence suggests microadenomas are being increasingly diagnosed. In addition, the clinical/biochemical phenotype appears to be more variable than previously suspected. We therefore examined the clinical, metabolic, biochemical and ra...

ea0025oc3.1 | Pituitary and thyroid | SFEBES2011

Development of a novel mass spectroscopy-based method for determining serum IGF1: assessment in a cohort of newly diagnosed subjects with acromegaly

Halsall David , Kay Richard , Taylor Kevin , Annamalai Anand , Kandasamy Narayanan , Wark Gwen , Pleasance Steve , Gurnell Mark

Background: The recently published ‘Consensus on Criteria for Cure of Acromegaly’ (Giustina et al. JCEM, 2010) highlighted concerns regarding the quality of currently available insulin-like growth factor 1 (IGF1) immunoassays which may contribute, at least in part, to the discordance between GH and IGF1 that is observed in up to 30% of patients with acromegaly after treatment. The development of mass spectroscopy (MS)-based technology has been proposed ...

ea0028p248 | Pituitary | SFEBES2012

‘Isolated acquired secondary hypogonadism’ in men referred to an adult endocrine clinic

Kandasamy Narayanan , Baxter Mark , Skittrall Jordan , Annamalai Anand Kumar , Antoun Nagui , Simpson Helen , Halsall David , Gurnell Mark

Background: Acquired male secondary hypogonadism is a relatively common cause of referral to the endocrine clinic. However, the extent to which further investigation is required, and the indications for a trial of testosterone therapy, remain unclear. Aim To review the clinical/biochemical/radiological findings in men presenting with this condition.Methods: We performed a retrospective case analysis of 41 consecutive patients referred to our clinic over ...

ea0028p267 | Pituitary | SFEBES2012

Potential pitfalls in the management of thyrotropinoma

Koulouri Olympia , Kandasamy Narayanan , Moran Carla , Melvin Alison , Donnelly Neil , Mannion Richard , Pickard John , Halsall David , Chatterjee Krishna , Gurnell Mark

Case Report: A 49-year-old man presented with a two-year history of thyrotoxic symptoms for which he had been investigated on several occasions. He had a past medical history of dilated cardiomyopathy, which had been attributed to excess alcohol consumption, and had also suffered episodes of non-sustained ventricular tachycardia. His family history was strongly positive for autoimmune thyroid disease. Eventually, he was found to have an elevated fT4 (53 pmol/L, RR 12–22) ...

ea0025p192 | Endocrine tumours and neoplasia | SFEBES2011

Familial adrenocortical carcinoma associated with HNPCC

Kandasamy Narayanan , Nik-Zainal Serena , Annamalai Anand Kumar , Walker Lisa , Happerfield Lisa C , Arends Mark J , Patterson Joan , Gurnell Mark

We report the first case of familial adrenocortical carcinoma (ACC) in association with hereditary non-polyposis colorectal cancer (HNPCC) in a family with a MSH2 germline mutation.HNPCC, an autosomal dominant disorder caused by mutations in one of the DNA mismatch repair (MMR) genes, is the commonest cause of hereditary colon carcinoma, and is associated with an increased risk of certain non-colonic cancers (e.g. endometrial, ovarian, urin...

ea0025p309 | Steroids | SFEBES2011

Utility of basal DHEAS measurement in the detection of subclinical autonomous glucocorticoid hypersecretion in adrenal incidentaloma

Annamalai Anand K , Kandasamy Narayanan , Freeman Natalie , Venugopal Kuhan , Chia Jonathan , Shaw Ashley , Simpson Helen L , Halsall David , Gurnell Mark

Background: Adrenal incidentalomas (AI) are identified in 4–7% of patients >40 years undergoing abdominal CT/MRI. Evidence of subclinical autonomous glucocorticoid hypersecretion (SAGH) is found in 5–10% of cases depending on the diagnostic criteria/thresholds adopted.Aim: To examine the utility of basal DHEAS measurement in the detection of SAGH in a cohort of patients with AI.Methods: Ninety-six consecutive subjects...

ea0034oc6.6 | Clinical | SFEBES2014

11C-methionine PET--CT co-registered with volume MRI: a novel adjunctive imaging modality to aid diagnosis and management in patients with pituitary adenomas

Koulouri Olympia , Kandasamy Narayanan , Powlson Andrew , Moran Carla , Cheow Heok , Antoun Nagui , Levy Miles , Hoole Andrew , Chatterjee Krishna , Donnelly Neil , Mannion Richard , Burnet Neil , Pickard John , Gurnell Mark

Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about ‘functionality’ of lesions (e.g. residual adenoma vs post-surgical scar tissue) and cannot reliably identify all microadenomas.We hypothesised that i) imaging with the PET ligand 11C-methionine, which is taken up at sites of peptide/protein synthesis, would permit more reliable identification of functioning pituitary adenoma ...

ea0031p263 | Pituitary | SFEBES2013

11C-methionine PET–CT co-registered with volume MRI identifies residual functioning tumour in acromegaly

Koulouri Olympia , Kandasamy Narayanan , Moran Carla , Chatterjee Krish , Halsall David , Cheow HK , Antoun Nagui , Hoole Andrew , Burnet Neil , Donnelly Neil , Mannion Richard , Pickard John , Gurnell Mark

Although MRI remains the investigation of choice for pituitary imaging, it does not reliably identify all secretory microadenomas, and cannot always discriminate residual tumour from post-surgical change following hypophysectomy. We hypothesised that i) imaging with the PET ligand 11C-methionine, which is taken up at sites of peptide/protein synthesis, would permit more reliable identification of functioning pituitary adenoma, and ii) co-registration of PET–CT ...